Exicure Provides Business Update Amid COVID-19 Pandemic
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE[1])–Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today provided an update on the Company’s operations in response to the global COVID-19 pandemic and the Company’s current evaluation of the impact the pandemic may have on the Company’s clinical trials, preclinical research and development (R&D) and general...
READ MORE Exicure Provides Business Update Amid COVID-19 Pandemic